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ECONOMIC ASPECTS OF INDIVIDUAL TREATMENT IN
POLAND—OUT–PATIENT VIEWPOINT
Czech M1, Horoszewska M2, Pachocki R1
1Servier Polska, Warsaw, Poland; 2Warsaw University of Technology,
Warsaw, Poland
Fast and dynamic development of medicine and pharmacy is
linked not only with efﬁcacy and safety of drugs but also with
their cost–effectiveness, especially when patients’ co-payment
systematically increases. OBJECTIVES: To investigate the recog-
nition of the term “pharmacoeconomics” by patients of an open
pharmacy and the role of economic aspects in decision making
concerning drug purchases. METHODS: A total of 270 patients
(170 suffering from chronic and 100 from acute diseases) were
interviewed (18 questions with a 5 level weighted / validity scale).
RESULTS: A total of 67% of respondents were able to deﬁne
(more or less precisely) the term “pharmacoeconomics”. Thirty
percent (30%) of patients treated acutely and eight 8% chroni-
cally were unable to pay for their prescriptions (level of co-
payment too high), which decreases their compliance (different
factors also apply). Price elasticity of demand was low: 67 out
of 100 treated chronically and 76 out of 100 treated acutely
would not have a prescription made up if the price of a drug
increased by 50%. On the other hand, 88% and 92% of patients
treated for chronic and acute diseases respectively would ﬁnd
sources of ﬁnance if non-treatment led to serious health conse-
quences and 93% of respondents would pay more for a drug if
they were sure it was absolutely safe. Forty percent (40%) of
respondents declared that they would like to use only drugs
which make them able to work, 81% prefer to take effective but
sometimes expensive drugs in order to shorten hospitalization
time. CONCLUSIONS: Elements of cost-effectiveness, relation-
ship between the price of a drug and its effectiveness and safety
as well as different cost components linked to a medical condi-
tion remain within the scope of interest of patients purchasing
drugs in pharmacy.
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PREFERENCES MATTER: UNDERSTANDING DEMAND FOR
VOLUNTARY HEALTH INSURANCE
De Allegri M1, Sanon M2, Bridges JFP1, Sauerborn R1
1University of Heidelberg, Heidelberg, Germany; 2Centre de
Recherche en Sante’ de Nouna, Nouna, Burkina Faso
OBJECTIVES: The aim of this study was to explore individual
and community factors affecting the decision making process
leading to purchase of voluntary health insurance among a rural
community in sub-Saharan Africa. Such intervention is crucial in
the context given that, by pooling resources and risks across a
community, it can increase equitable access to health care ser-
vices and reduce health disparities. METHODS: The study used
qualitative research methods to understand consumers’ prefer-
ences in relation to their decision to purchase voluntary health
insurance. This approach was considered preferable to quanti-
tative methods traditionally used in demand analysis because of
its potential to capture the complexity involved. Thirty-two
respondents were selected for an individual in-depth interview
using a stratiﬁed sampling design based on insurance status, dis-
tance to health facility and socio-economic status. All interviews
were tape recorded, fully translated and transcribed, analyzed
and triangulated by two independent researchers using Atlas.ti
software. Data from eight focus group discussions provided an
additional valuable source of triangulation. RESULTS: Partici-
pants, regardless of insurance status, understood the insurance
potential to decrease health inequalities by facilitating access to
Health Care services. They justiﬁed their decision to purchase or
not to purchase insurance in relation to their preference regard-
ing speciﬁc elements of the scheme, including the enrollment
unit, the beneﬁt package, the management structure, the
payment modalities, and the timing of the enrollment campaign.
CONCLUSIONS: The use of qualitative methods led to a thor-
ough investigation of consumers’ preferences. It allowed to for-
mulate clear and concise policy recommendations to be used to
redirect the scheme design. The qualitative approach proved to
be a valuable tool for understanding consumers’ preferences in
relation to the formulation of health policy suggesting that in
many circumstances, it is to be preferred to traditional quanti-
tative methods as an evaluation technique.
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OBJECTIVES: To analyze the effect of the introduction of phar-
macoeconomics evaluations in the creation of a positive drug list
in Bulgaria. METHODS: Legislation analysis of the current 
regulation for the creation of positive drug lists and its impact
on the number of medicines proposed for reimbursement and
included in the list. RESULTS: Regulation for the creation of
positive drug lists was issued in 2002 in Bulgaria with the aim
to establish clear criteria for the selection of medicines for the
reimbursement practice and decrease the number of reimbursed
drugs. The medicines were separated into three main classes—
originators; medicines for which there is a therapeutic alterna-
tive but which have higher efﬁciency or less adverse drug events,
and generic medicines. For the ﬁrst two groups, producers were
asked to prepare pharmacoeconomic evaluation following pre-
viously established form. Out of the 3500 dosage forms regis-
tered in the country as prescription medicines, 2852 dossies were
submitted, of which 2477 dosage forms were included in the pos-
itive drug list (550 INN). Originators account for 63%, imported
generics for 19% and domestic generics for 18%. Excluded 
medicines compose 45% originators, 20% imported generics,
18% domestic generics. In comparison with previously existing
drug lists, the number of drugs did not decrease signiﬁcantly.
Main difﬁculties during the evaluation process were lack of phar-
macoeconomics analysis within the country, lack of national
pharmacoeconomic guidelines and changes in the companies
pricing policy. CONCLUSIONS: The introduction of pharma-
coeconomic evaluation during the process of the creation of a
positive drug list in Bulgaria did not decrease the number of
selected medicines but stimulate companies to start developing
evaluations within the country.
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MEDICINAL CANNABIS IN THE NETHERLANDS
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OBJECTIVES: In The Netherlands, cannabis has been available
for medicinal purposes in pharmacies upon prescription by a
medical doctor since September 2003. This research was done to
study the characteristics of patients that start to use cannabis
from pharmacies. METHODS: A national enquiry was started
to identify all patients who were prescribed medicinal cannabis.
Patients were contacted by their pharmacist to ﬁll out a ques-
tionnaire. The questionnaire contained items about characteris-
tics of patients; complaints and morbidity; use of cannabis;
experiences with other cannabis products. Furthermore, history
of drug use was collected. RESULTS: In total, 200 patients
